At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,620 enrolled
Drug / intervention
niacin (+) laropiprant +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety and Tolerability of MK0524A in Patients With Primary Hypercholesterolemia or Mixed Hyperlipidemia
In Brief
A Phase 3 clinical trial evaluating niacin (+) laropiprant and ER-niacin for Primary Hypercholesterolaemia and Mixed Hyperlipidaemia. Completed, enrolled 1,620 participants.
Detailed Summary
A 28-week clinical trial in patients with primary hypercholesterolemia or mixed hyperlipidemia to study the effects of MK0524A on lipids and tolerability. There will be 9 scheduled clinic visits, and 3 treatment groups. A patient can be randomly assigned to 1 of the 3 treatment groups.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
Countries--
Collaborators--
Timeline
Phase 3CompletedFinished
2006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartDec 2005
First PostedDec 2005
Primary CompletionDec 2006
TodayJul 2026
First PostedDec 23, 2005
Enrollment StartDec 1, 2005
Primary CompletionDec 1, 2006
TodayJul 2, 2026
Enrollment to primary: 1 yearPosted 20.5 years ago
Interventions
niacin (+) laropiprantdrug
Duration of Treatment - 24 weeks
ER-niacindrug
Duration of Treatment - 24 weeks